Molnlycke
Mölnlycke Health Care, commonly referred to as Mölnlycke, is a leading global provider of wound care and surgical solutions, headquartered in Sweden (SE). Founded in 1849, the company has established a strong presence in Europe, North America, and Asia, focusing on innovative products that enhance patient outcomes. Mölnlycke is renowned for its advanced wound care products, including the Mepilex® range of foam dressings and the Safetac® technology, which minimises pain during dressing changes. The company’s commitment to quality and innovation has positioned it as a trusted partner in healthcare, achieving notable milestones such as ISO certification and recognition for its sustainability efforts. With a robust market position, Mölnlycke continues to lead the industry by prioritising patient safety and comfort, making significant contributions to the fields of wound management and surgical care.
DitchCarbon Score
How does Molnlycke's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Molnlycke's score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Molnlycke's reported carbon emissions
In 2024, Mölnlycke Health Care reported total carbon emissions of approximately 549,129,000 kg CO2e. This includes 52,356,000 kg CO2e from Scope 1 emissions, 10,513,000 kg CO2e from Scope 2 emissions (market-based), and a significant 486,261,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (312,323,000 kg CO2e) and upstream transportation and distribution (41,254,000 kg CO2e). Mölnlycke has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 emissions by 50% by 2030, using 2021 as the baseline year. Additionally, the company plans to increase its sourcing of renewable electricity from 23% in 2021 to 100% by the end of 2024 and maintain this level through 2030. For Scope 3 emissions, Mölnlycke targets a 20% reduction by 2028 from the same baseline. Long-term, Mölnlycke is committed to achieving net-zero emissions across its value chain by 2050, with a further goal of reducing Scope 1 and 2 emissions by 90% and Scope 3 emissions by 97% per ton of sold product by the same year. These targets align with the Science Based Targets initiative (SBTi) and reflect the company's commitment to sustainable practices in the healthcare sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 41,653,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 52,743,000 | 00,000,000 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 00,000,000 | 000,000 | 000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Molnlycke is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
